The EBOS Group Ltd (ASX: EBO) share price is in focus as the healthcare group delivered $13.5 billion in revenue, up 9.9%, and reported a net profit of $225.2 million for FY26, reflecting a 4.7% increase.
What did EBOS Group report?
- Revenue from continuing operations: $13,486.7 million, up 9.9% from FY25
- Reported net profit after tax (NPAT): $225.2 million, up 4.7%
- Underlying NPAT: $249.7 million, down 3.1% year on year
- Reported EBITDA: $598.7 million, up 7.8%
- Final dividend: NZD 61.5 cents per share, with a record date of 28 August 2026 and payment on 18 September 2026
- Net tangible assets per share: AUD $5.39, compared to $4.17 a year ago
What else do investors need to know?
EBOS Group’s FY26 results show continued momentum in revenue growth across both the pharmaceutical and animal care divisions. While underlying profit dipped slightly due to higher restructuring and transaction costs, reported profits rose.
The company continues to invest in distribution networks and digital capabilities. A steady final dividend rewards shareholders and may signal confidence in ongoing cash flow strength.
What’s next for EBOS Group?
Looking ahead, EBOS says it remains committed to expanding its footprint across the healthcare and animal care sectors. Continued investment in technology and infrastructure aims to support organic growth and potential acquisitions.
Management will likely focus on integrating recent acquisitions, improving operational efficiencies, and delivering value for shareholders in a competitive market.
EBOS Group share price snapshot
Over the past 12 months, EBOS shares have declined 50%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.
